Mentor/s
Dr. Deschenes
Participation Type
Poster
Abstract
Cancer vaccines are a new, transcendent form of treatment aimed at achieving remission for metastatic melanoma patients. Recent studies have shown that two main forms of these vaccines have emerged: dendritic cell vaccines and personalized neoantigen vaccines. Neither of these types of cancer vaccines are especially effective for the treatment of metastatic melanoma on their own. However, they become much more efficient when utilized in conjunction other immunotherapeutic methods. Dendritic cell vaccines are most effective when used with either Ipilimumab or Interferon-α treatments. Personalized neoantigen vaccines are most productive when used with an anti-PD1 treatment. Each of these vaccines, when paired with these additional treatments, increase T cell productivity, anti-tumor responses, and an overall immune system attack against the malignant cells. Unfortunately, these vaccines are also accompanied by some challenges, most focused upon the toxicity rates that occur from the supplemental treatments. After considering the results of many clinical trials and reviews regarding cancer vaccines, it can be concluded that dendritic cell and personalized neoantigen vaccines are ineffective on their own. The success of these vaccines exponentially increases when they are coupled with additional forms of immunotherapeutic treatments.
College and Major available
Biology
Location
Digital Commons & West Campus 2nd Floor University Commons
Start Day/Time
4-28-2023 12:00 PM
End Day/Time
4-28-2023 2:00 PM
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
Prize Categories
Most Scholarly Impact or Potential, Best Visuals, Best Writing
The Juxtaposition of Various Forms of Cancer Vaccines for Metastatic Melanoma
Digital Commons & West Campus 2nd Floor University Commons
Cancer vaccines are a new, transcendent form of treatment aimed at achieving remission for metastatic melanoma patients. Recent studies have shown that two main forms of these vaccines have emerged: dendritic cell vaccines and personalized neoantigen vaccines. Neither of these types of cancer vaccines are especially effective for the treatment of metastatic melanoma on their own. However, they become much more efficient when utilized in conjunction other immunotherapeutic methods. Dendritic cell vaccines are most effective when used with either Ipilimumab or Interferon-α treatments. Personalized neoantigen vaccines are most productive when used with an anti-PD1 treatment. Each of these vaccines, when paired with these additional treatments, increase T cell productivity, anti-tumor responses, and an overall immune system attack against the malignant cells. Unfortunately, these vaccines are also accompanied by some challenges, most focused upon the toxicity rates that occur from the supplemental treatments. After considering the results of many clinical trials and reviews regarding cancer vaccines, it can be concluded that dendritic cell and personalized neoantigen vaccines are ineffective on their own. The success of these vaccines exponentially increases when they are coupled with additional forms of immunotherapeutic treatments.
Students' Information
Abby Molloy, Major: Biology, Minor: Sociology, Honors student, Year of Graduation: 2023
Third Prize Writing Across the Curriculum 2023.